A psychedelic nasal spray requiring a much shorter period of clinical supervision has shown promise against ...

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US. The FDA first approved the Johnson & Johnson drug, called ...

Spravato nasal spray has been FDA approved to treat depression. Here's how the esketamine spray works, esketamine vs. ketamine, and potential risks.

The Food and Drug Administration has approved a new nasal spray for the treatment of severe depression. On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ...

The nasal spray has shown promise in treating depression when other meds don't. Popularly known as the street drug “Special-K,” ketamine is often used in hospitals as an anesthetic, too. But ...

A new depression medication related to the party drug Special K could revolutionize treatment of the condition affecting 16 million Americans.

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

Nasal spray for depression is promising, but precautions should be taken by Joan Cook, opinion contributor - 03/09/19 2:00 PM ET. by Joan Cook, opinion contributor - 03/09/19 2:00 PM ET.